Chunyu Jiang1, Jianbo Wang2, Yonggang Wang3, Jungong Zhao1, Yueqi Zhu1, Xu Ma1, Jia Zhou1, Xuebing Yan4. 1. Department of Radiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yi-Shan Road, Shanghai, 200233, People's Republic of China. 2. Department of Radiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yi-Shan Road, Shanghai, 200233, People's Republic of China. a602131499@163.com. 3. Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, 200233, People's Republic of China. 4. Department of General Surgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, 200233, People's Republic of China.
Abstract
PURPOSE: Transarterial chemoembolization (TACE) is used to treat unresectable bone and soft tissue sarcoma (STS) and as a pre-surgical adjuvant treatment. However, its efficiency for advanced STS is undetermined. This study evaluated TACE's efficiency in treating advanced STS and prognostic factors for patient survival. MATERIALS AND METHODS: We enrolled 39 patients with unresectable STS who underwent TACE as an alternative treatment during 2010-2014, with overall survival (OS) as the primary end point. Cancer pain was evaluated by visual analogue scores (VAS) before and after TACE procedures. Factors that affect survival were evaluated by multivariate analyses (Cox proportional hazard model). RESULTS: Mean OS after TACE was 23.7 ± 2.1 months, with 1-year OS 71.5 %, 2-year OS 45.8 %, and 3-year OS 32.5 %. Lesion number and tumor stage were key predictors of survival. TACE was found to decrease cancer pain VAS and increase relapse interval. Size of polyvinyl alcohol (PVA) particle diameter (P = 0.03) and imaging response (P = 0.044) were also found to affect relapse interval. CONCLUSION: TACE was an effective treatment for advanced STS, with a 32.5 % 3-year OS rate, and led to lower cancer pain VAS and longer relapse intervals than chemoinfusion only. Smaller PVA particles are preferable during the TACE procedure.
PURPOSE: Transarterial chemoembolization (TACE) is used to treat unresectable bone and soft tissue sarcoma (STS) and as a pre-surgical adjuvant treatment. However, its efficiency for advanced STS is undetermined. This study evaluated TACE's efficiency in treating advanced STS and prognostic factors for patient survival. MATERIALS AND METHODS: We enrolled 39 patients with unresectable STS who underwent TACE as an alternative treatment during 2010-2014, with overall survival (OS) as the primary end point. Cancer pain was evaluated by visual analogue scores (VAS) before and after TACE procedures. Factors that affect survival were evaluated by multivariate analyses (Cox proportional hazard model). RESULTS: Mean OS after TACE was 23.7 ± 2.1 months, with 1-year OS 71.5 %, 2-year OS 45.8 %, and 3-year OS 32.5 %. Lesion number and tumor stage were key predictors of survival. TACE was found to decrease cancer painVAS and increase relapse interval. Size of polyvinyl alcohol (PVA) particle diameter (P = 0.03) and imaging response (P = 0.044) were also found to affect relapse interval. CONCLUSION: TACE was an effective treatment for advanced STS, with a 32.5 % 3-year OS rate, and led to lower cancer painVAS and longer relapse intervals than chemoinfusion only. Smaller PVA particles are preferable during the TACE procedure.
Authors: Francesco Arrigoni; Federico Bruno; Luigi Zugaro; Alessandra Splendiani; Ernesto Di Cesare; Antonio Barile; Carlo Masciocchi Journal: Radiol Med Date: 2018-04-23 Impact factor: 3.469
Authors: Waldec Jorge David Filho; Angel Ayumi Tome Uchiyama; Catarina Marchon; Letícia Maria Duarte Lopes; Ana Luísa de Castro Baccarin; Bruna de Fina; Ricardo Virgílio Dos Santos; Francisco Leonardo Galastri Journal: Case Rep Oncol Date: 2021-11-25
Authors: Mao Qiang Wang; Jin Long Zhang; Kai Yuan; Bing Yuan; Feng Duan; Jie Yu Yan; Yan Wang; Jin Xin Fu Journal: Ther Adv Med Oncol Date: 2020-05-18 Impact factor: 8.168